In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Petrelintide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 22 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (12 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 12 · 6 active | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Petrelintide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weight | 77 | 83481717 |
| Adverse eventsWhole body |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
22
50449311 |
| Gastrointestinal adverse eventsGastrointestinal | 99 | 185185 |
|---|
| PharmacokineticsPharmacology | 33 | 969231 |
|---|
| MortalityWhole body | 11 | 504217 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 12 trials, ranked by phase, then posted results and enrollment: 3 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hoffmann-La Roche3,900 participants30 Sept 2026 to est. 22 Mar 2029
Obesity or Overweight
Hoffmann-La Roche2,500 participants30 Sept 2026 to est. 6 Oct 2030
Obesity or Overweight · Cardiovascular Disease
Hoffmann-La Roche600 participantsest. 30 Sept 2026 to est. 19 Jan 2029
Obesity or Overweight · Type 2 Diabetes
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Petrelintide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −8.1% Estimated treatment difference versus placebo · petrelintide 5·0 mg Dose studied: 5·0 mg once weekly28 weeksn = 1642026 | −5.8% Placebo-subtracted body weight change · liraglutide 3.0 mg, week 26 Dose studied: 3.0 mg26 weeksn not reported2021 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 20% Nausea incidence · petrelintide (79 of 404) Placebo (5 participants): 6% n = 4852026 | 45% Nausea incidence 8 weeksn = 20 |
−8.1%
Estimated treatment difference versus placebo · petrelintide 5·0 mg
Dose studied: 5·0 mg once weekly28 weeksn = 1642026
−5.8%
Placebo-subtracted body weight change · liraglutide 3.0 mg, week 26
Dose studied: 3.0 mg26 weeksn not reported2021
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Petrelintide | Liraglutide |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 3 randomized-trial results measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
20%
Nausea incidence · petrelintide (79 of 404)
Placebo (5 participants): 6%
n = 4852026
45%
Nausea incidence
8 weeksn = 202015
| Adverse eventsGastrointestinalCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 28% Serum lipase increase n = 9,3402017 |
|---|
No comparable result
3 randomized-trial results measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No comparable result
2 randomized-trial results measure it in another way or another unit.
28%
Serum lipase increase
n = 9,3402017